Medline (NASDAQ:MDLN) Research Coverage Started at BMO Capital Markets

BMO Capital Markets initiated coverage on shares of Medline (NASDAQ:MDLN) in a research note published on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $45.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on MDLN. Mizuho began coverage on shares of Medline in a report on Monday. They issued an “outperform” rating and a $48.00 price objective for the company. Wolfe Research assumed coverage on Medline in a report on Monday. They set an “outperform” rating and a $47.00 target price on the stock. Morgan Stanley began coverage on Medline in a research note on Sunday. They set an “overweight” rating and a $48.00 price target for the company. Wells Fargo & Company initiated coverage on Medline in a report on Monday. They set an “equal weight” rating and a $42.00 price objective on the stock. Finally, Baird R W upgraded Medline to a “strong-buy” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.70.

Medline Trading Up 1.3%

MDLN stock opened at $43.41 on Monday. Medline has a 12 month low of $34.89 and a 12 month high of $45.50.

Insider Buying and Selling

In related news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Andrew J. Mills bought 2,586,206 shares of the stock in a transaction on Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the acquisition, the director directly owned 2,586,206 shares in the company, valued at approximately $74,999,974. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.